Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 13/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777216 | 0.91 | SSTR5 (0.49) | SSTR5SSTR1HRH1HTR2BACHE | |
| SCHEMBL3773095 | 0.91 | SSTR5 (0.51) | SSTR5HRH1HTR2B | |
| SCHEMBL3775982 | 0.88 | SSTR5 (0.50) | SSTR5SSTR1HRH1HTR2BACHE | |
| SCHEMBL3785418 | 0.88 | SSTR5 (0.53) | SSTR5SSTR1HRH1HTR2BACHE | |
| SCHEMBL3781606 | 0.86 | SSTR5 (0.56) | SSTR5 | |
| SCHEMBL4756346 | 0.85 | SSTR5 (0.49) | SSTR5SSTR1HRH1HTR2BACHE | |
| SCHEMBL3777223 | 0.84 | SSTR5 (0.48) | SSTR5SSTR1HRH1HTR2BACHE | |
| SCHEMBL3770113 | 0.82 | SSTR5 (0.51) | SSTR5HRH1HTR2BEHMT2 | |
| SCHEMBL3775646 | 0.81 | SSTR5 (0.46) | SSTR5SSTR1HRH1HTR2BEHMT2 | |
| SCHEMBL3775232 | 0.80 | SSTR5 (0.62) | SSTR5SSTR1HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | SSTR5 1/4885SSTR1 3/4885HRH1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.